Le Lézard
Classified in: Health
Subject: v

Sienna Announces October Dividend


MARKHAM, Ontario, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of October 2023, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on November 15, 2023 to shareholders of record as at October 31, 2023.

The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

About Sienna Senior Living

Sienna Senior Living Inc. (TSX:SIA) offers a full range of seniors' living options, including independent living and assisted living under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.

For further information, please contact:
David Hung
Chief Financial Officer & Executive Vice President
(905) 489-0258
[email protected]



These press releases may also interest you

9 nov 2024
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today shared progress of its Tmodtm CAR T-cell clinical programs...

9 nov 2024
WhatJobs has launched a dedicated initiative to support Ukrainian children affected by the ongoing war. Partnering with U4UKids, a U.S.-based charity, WhatJobs will donate 100% of its Ukrainian platform profits to provide essential medical, mental...

9 nov 2024
STARt-001 is the first clinical study to evaluate Marengo's novel, selective V? TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancersInvikafusp alfa, a...

9 nov 2024
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of clinical and...

9 nov 2024
On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International  Congress of the Asian Oncology Society (AOS2024) . This...

8 nov 2024
Mirum Pharmaceuticals, Inc. today announced that on November 8, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050...



News published on and distributed by: